Dashboard
Manage Tickers

PSTVPLUS THERAPEUTICS, INC.

Nasdaq plustherapeutics.com


$ 2.27 $ 0.15 (6.91 %)    

Wednesday, 15-May-2024 14:54:40 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 2.32
$ 2.22
$ 0.00 x 0
$ 2.32 x 200
$ 2.20 - $ 2.38
$ 0.97 - $ 4.45
179,486
na
10.03M
$ 1.25
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 03-05-2024 12-31-2023 10-K
3 10-31-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 04-20-2023 03-31-2023 10-Q
6 02-23-2023 12-31-2022 10-K
7 10-20-2022 09-30-2022 10-Q
8 07-21-2022 06-30-2022 10-Q
9 04-21-2022 03-31-2022 10-Q
10 02-24-2022 12-31-2021 10-K
11 10-21-2021 09-30-2021 10-Q
12 07-22-2021 06-30-2021 10-Q
13 04-22-2021 03-31-2021 10-Q
14 02-22-2021 12-31-2020 10-K
15 10-22-2020 09-30-2020 10-Q
16 08-10-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-30-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-15-2019 06-30-2019 10-Q
21 05-14-2019 03-31-2019 10-Q
22 03-29-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-11-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-11-2017 06-30-2017 10-Q
29 05-12-2017 03-31-2017 10-Q
30 03-24-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-11-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-10-2015 06-30-2015 10-Q
37 05-11-2015 03-31-2015 10-Q
38 03-16-2015 12-31-2014 10-K
39 11-07-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

plus-therapeutics-q1-2024-gaap-eps-075-beats-109-estimate-sales-1677m-miss-1688m-estimate
Plus Therapeutics Q1 2024 GAAP EPS $(0.75)...
05/15/2024 20:34:53

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(1...

plus-therapeutics-has-acquired-assets-for-the-synergistic-leptomeningeal-metastases-diagnostic-platform-financial-terms-not-disclosed-topline-clinical-trial-data-on-the-foresee-trial-met-its-primary-endpoint-of-clinical-utility
Plus Therapeutics Has Acquired Assets For ...
05/09/2024 15:36:06

CNSide can significantly improve LM diagnostic accuracy and the market size for Plus' lead LM radiotherapeutic candidate rh...

plus-therapeutics-shares-are-trading-higher-after-the-company-announced-a-private-placement-financing-of-up-to-18-million
Plus Therapeutics shares are trading highe...
05/06/2024 11:36:29

plus-therapeutics-announced-private-placement-of-up-to-approximately-18m-in-gross-proceeds-including-initial-upfront-funding-of-approximately-65m-and-up-to-an-additional-approximately-115m-upon-cash-exercise-of-accompanying-warrants-at-the-election
Plus Therapeutics Announced Private Placem...
05/06/2024 11:33:54

micro-cap-brain-cancer-focused-plus-therapeutics-poised-to-receive-3m-from-us-department-of-defense
Micro-Cap Brain Cancer Focused Plus Therap...
04/22/2024 11:00:19

Plus Therapeutics will secure $3 million in funding from the Department of Defense for pediatric brain cancer trial expansion.

plus-therapeutics-says-plus-now-has-23-million-in-active-awards-support-for-the-companys-targeted-radiotherapeutic-pipeline
Plus Therapeutics Says 'Plus now has $23 m...
04/22/2024 11:00:15

plus-therapeutics-receives-3m-award-recommendation-from-the-us-department-of-defense
Plus Therapeutics Receives $3M Award Recom...
04/22/2024 11:00:08

plus-therapeutics-announces-validation--clinical-implementation-of-csf-01-leptomeningeal-cancer-cell-diagnostic
Plus Therapeutics Announces Validation & C...
03/25/2024 12:09:31

Plus' CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma an...

plus-therapeutics-has-completed-dosing-in-cohort-5-of-respect-lm-phase-1-dose-escalation-trial-of-rhenium-186re-obisbemeda-for-leptomeningeal-metastases-from-solid-tumors-company-expects-moving-into-cohort-6-in-q2-2024-following-standard-safety-review
Plus Therapeutics Has Completed Dosing In ...
03/11/2024 11:21:12

recap-plus-therapeutics-q4-earnings
Recap: Plus Therapeutics Q4 Earnings
03/05/2024 21:35:11

plus-therapeutics-q4-eps-070-beats-107-estimate-sales-131m-beat-106m-estimate
Plus Therapeutics Q4 EPS $(0.70) Beats $(1...
03/05/2024 21:30:53

Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.70) per share which beat the analyst consensus estimate of $(1...

earnings-scheduled-for-march-5-2024
Earnings Scheduled For March 5, 2024
03/05/2024 10:00:02

Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2...

plus-therapeutics-earnings-preview
Plus Therapeutics Earnings Preview
03/04/2024 18:03:14

plus-therapeutics-says-the-award-payment-of-33m-together-with-its-cash-on-hand-provides-sufficient-runway-to-fund-operations-to-2h-2025
Plus Therapeutics Says The Award Payment O...
12/18/2023 12:21:11

The Company forecasts an additional $6.9 million in grant revenue during the 2024 calendar year.

plus-therapeutics-partners-with-k2bio-to-develop-novel-tests-for-cerebrospinal-fluid-csf-tumor-cell-and-molecular-biomarker-analyses
Plus Therapeutics Partners With K2bio To D...
12/12/2023 13:02:26

12-health-care-stocks-moving-in-mondays-intraday-session
12 Health Care Stocks Moving In Monday's I...
11/20/2023 17:31:10

insiders-buying-plus-therapeutics-and-2-other-stocks-under-2
Insiders Buying Plus Therapeutics And 2 Ot...
11/09/2023 13:51:50

The Dow Jones closed lower by around 40 points on Wednesday. When insiders purchase or sell shares, it indicates their confiden...

plus-therapeutics-says-it-has-been-granted-us-fda-orphan-drug-designation-to-rhenium-186re-obisbemeda-for-breast-cancer-treatment-with-leptomeningeal-metastases
Plus Therapeutics Says It Has Been Granted...
11/03/2023 11:05:27

why-plus-therapeutics-stock-popped-today
Why Plus Therapeutics Stock Popped Today
11/01/2023 19:38:49

PLUS THERAPEUTICS, Inc. (NASDAQ: PSTV) shares are trading higher on Wednesday.

why-extreme-networks-shares-are-trading-lower-by-around-15-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Extreme Networks Shares Are Trading Lo...
11/01/2023 17:59:52

Gainers

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION